- Home
- HE vs APGE Comparison
HE vs APGE Comparison
Compare HE & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- APGE
- Stock Information
- Founded
- HE 1891
- APGE 2022
- Country
- HE United States
- APGE United States
- Employees
- HE N/A
- APGE N/A
- Industry
- HE Electric Utilities: Central
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HE Utilities
- APGE Health Care
- Exchange
- HE Nasdaq
- APGE Nasdaq
- Market Cap
- HE 1.9B
- APGE 2.1B
- IPO Year
- HE N/A
- APGE 2023
- Fundamental
- Price
- HE $10.50
- APGE $37.29
- Analyst Decision
- HE Hold
- APGE Strong Buy
- Analyst Count
- HE 4
- APGE 4
- Target Price
- HE $11.00
- APGE $91.33
- AVG Volume (30 Days)
- HE 1.5M
- APGE 545.3K
- Earning Date
- HE 05-09-2025
- APGE 05-20-2025
- Dividend Yield
- HE N/A
- APGE N/A
- EPS Growth
- HE N/A
- APGE N/A
- EPS
- HE N/A
- APGE N/A
- Revenue
- HE $3,219,850,000.00
- APGE N/A
- Revenue This Year
- HE $23.08
- APGE N/A
- Revenue Next Year
- HE $1.74
- APGE $743.14
- P/E Ratio
- HE N/A
- APGE N/A
- Revenue Growth
- HE N/A
- APGE N/A
- 52 Week Low
- HE $7.61
- APGE $26.20
- 52 Week High
- HE $18.19
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- HE 53.60
- APGE 52.37
- Support Level
- HE $10.14
- APGE $34.38
- Resistance Level
- HE $10.55
- APGE $41.05
- Average True Range (ATR)
- HE 0.29
- APGE 2.23
- MACD
- HE 0.04
- APGE 0.10
- Stochastic Oscillator
- HE 77.05
- APGE 51.48
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.